Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience

被引：0
|
作者：
Yoshihide Ueda
Toru Ikegami
Nobuhisa Akamatsu
Akihiko Soyama
Masahiro Shinoda
Ryoichi Goto
Hideaki Okajima
Tomoharu Yoshizumi
Akinobu Taketomi
Yuko Kitagawa
Susumu Eguchi
Norihiro Kokudo
Shinji Uemoto
Yoshihiko Maehara
机构：
[1] Kyoto University,Department of Gastroenterology and Hepatology, Graduate School of Medicine
[2] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences
[3] University of Tokyo,Division of Artificial Organ and Transplantation, Department of Surgery
[4] Nagasaki University Graduate School of Biomedical Sciences,Department of Surgery
[5] Keio University School of Medicine,Department of Surgery
[6] Hokkaido University Graduate School of Medicine,Department of Gastroenterological Surgery I
[7] Kyoto University,Department of Surgery, Graduate School of Medicine
来源：
Journal of Gastroenterology | 2017年 / 52卷
关键词：
Hepatitis C; Liver transplantation; Living donor; Sofosbuvir; Ledipasvir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：986 / 991
页数：5
相关论文
共 50 条
  • [1] Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience
    Ueda, Yoshihide
    Ikegami, Toru
    Akamatsu, Nobuhisa
    Soyama, Akihiko
    Shinoda, Masahiro
    Goto, Ryoichi
    Okajima, Hideaki
    Yoshizumi, Tomoharu
    Taketomi, Akinobu
    Kitagawa, Yuko
    Eguchi, Susumu
    Kokudo, Norihiro
    Uemoto, Shinji
    Maehara, Yoshihiko
    JOURNAL OF GASTROENTEROLOGY, 2017, 52 (08) : 986 - 991
  • [2] Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C after living donor liver transplantation: a Japanese multicenter experience
    Ueda, Y.
    Ikegami, T.
    Akamatsu, N.
    Soyama, A.
    Shinoda, M.
    Goto, R.
    Okajima, H.
    Yoshizumi, T.
    Taketomi, A.
    Kitagawa, Y.
    Eguchi, S.
    Kokudo, N.
    Uemoto, S.
    Maehara, Y.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S747 - S747
  • [3] Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant
    Mohamed Shoreibah
    Jordan Orr
    DeAnn Jones
    Jie Zhang
    Krishna Venkata
    Omar Massoud
    Hepatology International, 2017, 11 : 434 - 439
  • [4] Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant
    Shoreibah, Mohamed
    Orr, Jordan
    Jones, DeAnn
    Zhang, Jie
    Venkata, Krishna
    Massoud, Omar
    HEPATOLOGY INTERNATIONAL, 2017, 11 (05) : 434 - 439
  • [5] Sofosbuvir/Ledipasvir without Ribavirin is effective in the treatment of recurrent hepatitis C infection post liver transplant
    Shoreibah, Mohamed G.
    Jones, Deann
    Orr, Jordan
    Zhang, Jie
    Venkata, Krishna V.
    Massoud, Omar I.
    HEPATOLOGY, 2016, 64 : 995A - 996A
  • [6] Multicenter Experience using Sofosbuvir/Ledipasvir with or without Ribavirin to Treat Hepatitis C Genotype 1 Relapsers after Simeprevir and Sofosbuvir Treatment
    Pungpapong, Surakit
    Leise, Michael D.
    Watt, Kymberly D.
    Vargas, Hugo E.
    Keaveny, Andrew P.
    Aqel, Bashar A.
    HEPATOLOGY, 2015, 62 : 716A - 716A
  • [7] Simeprevir and Sofosbuvir With or Without Ribavirin to Treat Recurrent Genotype 1 Hepatitis C Virus Infection After Orthotopic Liver Transplantation
    Crittenden, Neil E.
    Buchanan, Laura A.
    Pinkston, Christina M.
    Cave, Barbra
    Barve, Ashutosh
    Marsano, Luis
    McClain, Craig James
    Jones, Christopher M.
    Marvin, Michael R.
    Davis, Eric G.
    Kuns-Adkins, Candice B.
    Gedaly, Roberto
    Brock, Guy
    Shah, Malay B.
    Rosenau, Jens
    Cave, Matthew C.
    LIVER TRANSPLANTATION, 2016, 22 (05) : 635 - 643
  • [8] Sustained virologic response after eight weeks of treatment with sofosbuvir, ledipasvir, and ribavirin in a decompensated cirrhotic patient with hepatitis C virus genotype 1b
    Taniyama, Ohki
    Mawatari, Seiichi
    Oda, Kohei
    Tabu, Kazuaki
    Ijuin, Sho
    Kumagai, Kotaro
    Kasai, Ai
    Tashima, Shuzo
    Tamai, Tsutomu
    Moriuchi, Akihiro
    Ido, Akio
    HEPATOLOGY RESEARCH, 2019, 49 (02) : 239 - 243
  • [9] Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation
    Charlton, Michael
    Gane, Edward
    Manns, Michael P.
    Brown, Robert S., Jr.
    Curry, Michael P.
    Kwo, Paul Y.
    Fontana, Robert J.
    Gilroy, Richard
    Teperman, Lewis
    Muir, Andrew J.
    McHutchison, John G.
    Symonds, William T.
    Brainard, Diana
    Kirby, Brian
    Dvory-Sobol, Hadas
    Denning, Jill
    Arterburn, Sarah
    Samuel, Didier
    Forns, Xavier
    Terrault, Norah A.
    GASTROENTEROLOGY, 2015, 148 (01) : 108 - 117
  • [10] The Efficacy of Sofosbuvir/Ledipasvir or Sofosbuvir Based Therapies for Recurrent Hepatitis C (Genotype 1, 2) in Living Donor Liver Transplantation Recipient
    Hu, Tsung-Hui
    Chen, Chao-Long
    Lin, Chi-Che
    Lin, Yu-Hung
    TRANSPLANTATION, 2016, 100 : S254 - S254
12345